I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The Prescribing Clinical Network recommends Golimumab as a treatment option for non-radiographic axial spondyloarthritis in line with NICE TA497 (January 2018). Golimumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians) Golimumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.
